| Name | Title | Contact Details |
|---|
Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women’s health and neuroendocrine disorders.
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.
At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.
3 Prime is a Aston, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.